PAX Financial Group LLC Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

PAX Financial Group LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 36.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,143 shares of the biopharmaceutical company’s stock after selling 2,957 shares during the period. PAX Financial Group LLC’s holdings in Gilead Sciences were worth $475,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in GILD. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences in the fourth quarter worth $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GILD. Royal Bank of Canada lifted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Bank of America boosted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Stock Down 4.6 %

Shares of NASDAQ GILD opened at $107.25 on Friday. The stock has a market capitalization of $133.54 billion, a P/E ratio of 289.86, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm’s 50 day simple moving average is $107.30 and its two-hundred day simple moving average is $95.80. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 in the last ninety days. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.